(SUPN) Supernus Pharmaceuticals - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 2.798m USD | Total Return: 45.8% in 12m
Avg Turnover: 29.8M
EPS Trend: 30.5%
Qual. Beats: 0
Rev. Trend: 88.2%
Qual. Beats: 4
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) is a biopharmaceutical firm focused on the development and commercialization of therapies for central nervous system (CNS) disorders. The company’s portfolio includes treatments for ADHD, Parkinson’s disease, epilepsy, and migraine prophylaxis, with key products such as Qelbree, GOCOVRI, and Oxtellar XR. Its commercial strategy utilizes a network of specialty pharmacies and pharmaceutical wholesalers to distribute proprietary extended-release formulations.
The CNS pharmaceutical sector is characterized by high barriers to entry due to stringent FDA regulatory requirements and the complexity of blood-brain barrier drug delivery. Supernus maintains a late-stage pipeline, including SPN-817 and SPN-820, to address unmet needs in treatment-resistant depression and rare seizure disorders. Investors may find it useful to examine ValueRay for deeper fundamental analysis of the companys valuation.
Founded in 2005 and headquartered in Rockville, Maryland, the company operates under a business model that integrates internal research and development with strategic partnerships. This approach allows Supernus to advance multiple clinical trials simultaneously while managing the significant capital expenditures typical of the drug development lifecycle.
- Qelbree prescription growth in adult ADHD market offsets legacy product revenue erosion
- FDA approval status of SPN-830 apomorphine pump impacts long-term Parkinson’s franchise
- Generic competition for Trokendi XR and Oxtellar XR pressures overall gross margins
- Success of Phase 2 clinical trials for SPN-817 and SPN-820 dictates pipeline valuation
- Strategic capital allocation toward accretive CNS asset acquisitions drives inorganic revenue growth
| Net Income: -29.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -6.64 > 1.0 |
| NWC/Revenue: 46.04% < 20% (prev 60.75%; Δ -14.71% < -1%) |
| CFO/TA 0.06 > 3% & CFO 83.3m > Net Income -29.0m |
| Net Debt (-343.3m) to EBITDA (43.4m): -7.90 < 3 |
| Current Ratio: 1.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (57.6m) vs 12m ago 3.19% < -2% |
| Gross Margin: 89.42% > 18% (prev 0.88%; Δ 8.85k% > 0.5%) |
| Asset Turnover: 54.55% > 50% (prev 49.58%; Δ 4.97% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.24 (Total Current Assets 731.6m - Total Current Liabilities 373.9m) / Total Assets 1.50b |
| B: 0.34 (Retained Earnings 515.6m / Total Assets 1.50b) |
| C: -0.04 (EBIT TTM -53.9m / Avg Total Assets 1.42b) |
| D: 1.22 (Book Value of Equity 515.4m / Total Liabilities 423.9m) |
| Altman-Z'' = 3.71 = AA |
| DSRI: 1.08 (Receivables 182.2m/145.6m, Revenue 776.8m/668.0m) |
| GMI: 0.99 (GM 89.42% / 88.42%) |
| AQI: 1.01 (AQ_t 0.49 / AQ_t-1 0.48) |
| SGI: 1.16 (Revenue 776.8m / 668.0m) |
| TATA: -0.07 (NI -29.0m - CFO 83.3m) / TA 1.50b) |
| Beneish M = -2.93 (Cap -4..+1) = A |
As of May 30, 2026, the stock is trading at USD 46.18 with a total of 458,652 shares traded.
Over the past week, the price has changed by -6.48%,
over one month by -4.88%,
over three months by -15.62% and
over the past year by +45.77%.
Supernus Pharmaceuticals has received a consensus analysts rating of 3.80. Therefore, it is recommended to hold SUPN.
- StrongBuy: 2
- Buy: 0
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 62.8 | 36.1% |
P/E Forward = 20.1613
P/S = 3.6019
P/B = 2.5985
P/EG = 1.47
Revenue TTM = 776.8m USD
EBIT TTM = -53.9m USD
EBITDA TTM = 43.4m USD
Long Term Debt = 30.3m USD (estimated: total debt 40.9m - short term 10.6m)
Short Term Debt = 10.6m USD (from shortTermDebt, last quarter)
Debt = 40.9m USD (from shortLongTermDebtTotal, last quarter) (leases 40.9m already included)
Net Debt = -343.3m USD (calculated: Debt 40.9m - CCE 384.2m)
Enterprise Value = 2.45b USD (2.80b + Debt 40.9m - CCE 384.2m)
Interest Coverage Ratio = unknown (Ebit TTM -53.9m / Interest Expense TTM 0.0)
EV/FCF = 29.85x (Enterprise Value 2.45b / FCF TTM 82.2m)
FCF Yield = 3.35% (FCF TTM 82.2m / Enterprise Value 2.45b)
FCF Margin = 10.59% (FCF TTM 82.2m / Revenue TTM 776.8m)
Net Margin = -3.74% (Net Income TTM -29.0m / Revenue TTM 776.8m)
Gross Margin = 89.42% ((Revenue TTM 776.8m - Cost of Revenue TTM 82.2m) / Revenue TTM)
Gross Margin QoQ = 88.74% (prev 89.13%)
Tobins Q-Ratio = 1.64 (Enterprise Value 2.45b / Total Assets 1.50b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 40.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -42.6m (EBIT -53.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.96 (Total Current Assets 731.6m / Total Current Liabilities 373.9m)
Debt / Equity = 0.04 (Debt 40.9m / totalStockholderEquity, last quarter 1.08b)
Debt / EBITDA = -7.90 (Net Debt -343.3m / EBITDA 43.4m)
Debt / FCF = -4.17 (Net Debt -343.3m / FCF TTM 82.2m)
Total Stockholder Equity = 1.06b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.04% (Net Income -29.0m / Total Assets 1.50b)
RoE = -2.73% (Net Income TTM -29.0m / Total Stockholder Equity 1.06b)
RoCE = -4.93% (EBIT -53.9m / Capital Employed (Equity 1.06b + L.T.Debt 30.3m))
RoIC = -5.65% (negative operating profit) (NOPAT -42.6m / Invested Capital 753.2m)
WACC = 7.10% (E(2.80b)/V(2.84b) * Re(7.20%) + D(40.9m)/V(2.84b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 7.20% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.67 | Cagr: 2.06%
[DCF] Terminal Value 73.10% ; FCFF base≈114.7m ; Y1≈100.6m ; Y5≈81.3m
[DCF] Fair Price = 28.39 (EV 1.30b - Net Debt -343.3m = Equity 1.65b / Shares 58.0m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 30.53 | EPS CAGR: 5.04% | SUE: -0.20 | # QB: 0
Revenue Correlation: 88.21 | Revenue CAGR: 7.60% | SUE: 1.93 | # QB: 4
EPS current Quarter (2026-06-30): EPS=0.47 | Chg30d=-12.96% | Revisions=+20% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.70 | Chg30d=-2.08% | Revisions=N/A | Analysts=2
EPS current Year (2026-12-31): EPS=2.67 | Chg30d=+13.11% | Revisions=N/A | GrowthEPS=+11.7% | GrowthRev=+20.2%
EPS next Year (2027-12-31): EPS=4.37 | Chg30d=+3.48% | Revisions=N/A | GrowthEPS=+63.2% | GrowthRev=+18.2%
[Analyst] Revisions Ratio: +20%